Nanexa AB
556833-0285ActiveNanexa redefines injectables using proprietary nanoengineering drug delivery technology.
Yleiskatsaus
- 10–19
- Työntekijät
- 5–10milj SEK
- Liikevaihto
- 2010
- Perustettu
Avainpäättäjät
Anders Johansson
Head of Intellectual Property
David Westberg
Chief Executive Officer
Bridget Lacey
Chief Business Officer
Göran Ando
Chairman of the Board
+15 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Nanexa is a pharmaceutical development company specializing in advanced drug delivery systems. Their core innovation is the proprietary PharmaShell® technology, which utilizes Atomic Layer Deposition (ALD) precision. This technology is designed to transform drug administration by enabling long-actin...
Tunnisteet
Avainsanat
Teknologiat
Yritystiedot
- Toimiala
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Oikeudellinen muoto
- Aktiebolag
- ALV-numero
- SE556833028501
Päättäjät
19 yhteystietoa FunnelfeedrissäAnders Johansson
Head of Intellectual Property
David Westberg
Chief Executive Officer
Bridget Lacey
Chief Business Officer
Göran Ando
Chairman of the Board
Marie Gårdmark
Director Regulatory Affairs
Cecilia Danckwardt-Lillieström
Chief Financial Officer
Bengt Gustavsson
Board Member
Polla Rouf
Head of R&D ALD
Sven Undeland
Director Strategic Market Analysis
Jonas Fransson
Head of Pharmaceutical Development
Mikael Asp
Head of Quality Assurance, Special Advisor
Jakob Dynnes Hansen
Board Member
Richard Davis
Board Member
Kristine Bäck
Director Project Management
Joel Hellrup
Head of Pharmaceutical R&D
Mårten Rooth
Chief Technology Officer, Co-founder
Hanna Tilus
Board Member
Birgit Stattin Norinder
Board Member
Björn Svanström
current CFO (leaving)
Samankaltaiset yritykset
20 samankaltaista yritystä Funnelfeedrissä
NACAMED AS
Developing silicon nanoparticles for controlled, enhanced drug delivery systems.
Iconovo AB
10–19 työntekijätLeading partner developing patented dry powder inhaler drug delivery systems.
Double Bond Pharmaceutical AB
5–9 työntekijätDeveloping advanced drug delivery systems for targeted cancer and pneumonia treatment.
AcroPharma AB (publ)
0 työntekijätDeveloping innovative preventive therapeutics for major human diseases.
PILA PHARMA AB
1–4 työntekijätClinical stage biotech developing an oral obesity and diabetes treatment.
Selaa lisää
Kysymyksiä yrityksestä Nanexa AB
Haluatko nähdä Funnelfeedrin toiminnassa?
Varaa ilmainen demo ja tutustu siihen, miten Funnelfeedr auttaa sinua löytämään ja konvertoimaan ihanteelliset asiakkaasi.
Varaa demo